Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer

被引：10

作者：

Block, Matthew S. ^{[1
]}

Charbonneau, Bridget ^{[2
]}

Vierkant, Robert A. ^{[3
]}

Fogarty, Zachary ^{[3
]}

Bamlet, William R. ^{[3
]}

Pharoah, Paul D. P. ^{[34
,35
]}

Chenevix-Trench, Georgia ^{[44
]}

Rossing, Mary Anne ^{[6
,7
]}

Cramer, Daniel ^{[8
,9
,10
]}

Pearce, Celeste Leigh ^{[11
]}

Schildkraut, Joellen ^{[18
,19
]}

Menon, Usha ^{[36
]}

Kjaer, Susanne K. ^{[21
,49
]}

Levine, Douglas A. ^{[22
]}

Gronwald, Jacek ^{[51
]}

Culver, Hoda Anton ^{[13
]}

Whittemore, Alice S. ^{[14
]}

Karlan, Beth Y. ^{[15
]}

Lambrechts, Diether ^{[56
,57
]}

Wentzensen, Nicolas ^{[17
]}

Kupryjanczyk, Jolanta ^{[52
]}

Chang-Claude, Jenny ^{[61
]}

Bandera, Elisa V. ^{[24
]}

Hogdall, Estrid ^{[49
,50
]}

Heitz, Florian ^{[62
,64
]}

Kaye, Stanley B. ^{[40
,41
]}

Fasching, Peter A. ^{[12
,60
]}

Campbell, Ian ^{[45
,46
]}

Goodman, Marc T. ^{[16
]}

Pejovic, Tanja ^{[26
,27
]}

Bean, Yukie T. ^{[26
,27
]}

Hays, Laura E. ^{[28
,29
]}

Lurie, Galina ^{[30
]}

Eccles, Diana ^{[39
]}

Hein, Alexander ^{[60
]}

Beckmann, Matthias W. ^{[60
]}

Ekici, Arif B. ^{[65
]}

Paul, James ^{[43
]}

Brown, Robert ^{[37
]}

Flanagan, James M. ^{[37
]}

Harter, Philipp ^{[62
,64
]}

du Bois, Andreas ^{[62
,64
]}

Schwaab, Ira ^{[63
]}

Hogdall, Claus K. ^{[21
]}

Lundvall, Lene ^{[21
]}

Olson, Sara H. ^{[23
]}

Orlow, Irene ^{[23
]}

Paddock, Lisa E. ^{[25
]}

Rudolph, Anja ^{[61
]}

Eilber, Ursula ^{[61
]}

机构：

[1] Mayo Clin, Dept Med Oncol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA

[3] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA

[4] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA

[5] Mayo Clin, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA

[6] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98195 USA

[7] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[8] Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA

[9] Harvard Univ, Sch Med, Boston, MA USA

[10] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA

[11] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Keck Sch Med, Los Angeles, CA USA

[12] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA

[13] Univ Calif Irvine, Sch Med, Ctr Canc Genet Res & Prevent, Dept Epidemiol, Irvine, CA 92717 USA

[14] Stanford Univ, Sch Med, Dept Hlth Res & Policy Epidemiol, Palo Alto, CA 94304 USA

[15] Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA USA

[16] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[17] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA

[18] Duke Univ, Med Ctr, Duke Canc Inst, Canc Prevent Detect & Res Program, Durham, NC USA

[19] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA

[20] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA

[21] Rigshosp, Juliane Marie Ctr, Dept Obstet & Gynecol, DK-2100 Copenhagen, Denmark

[22] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10021 USA

[23] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[24] Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ USA

[25] New Jersey Dept Hlth, Trenton, NJ USA

[26] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA

[27] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[28] Dept Hematol & Oncol, Portland, OR USA

[29] Knight Canc Inst, Portland, OR USA

[30] Univ Hawaii, Ctr Canc, Canc Epidemiol Program, Honolulu, HI 96822 USA

[31] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Div Populat Sci, Tampa, FL USA

[32] Geisel Sch Med Dartmouth, Epidemiol & Biostat Sect, Lebanon, NH USA

[33] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA

[34] Univ Cambridge, Dept Oncol, Cambridge CB2 1TN, England

[35] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB2 1TN, England

[36] UCL, Inst Womens Hlth, Gynaecol Canc Res Ctr, London WC1E 6BT, England

[37] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London SW7 2AZ, England

[38] Break Breast Canc Res Ctr, London, England

[39] Univ Southampton, Southampton Univ Hosp, Fac Med, Southampton SO9 5NH, Hants, England

[40] Inst Canc Res, Div Clin Studies, Sutton, Surrey, England

[41] Royal Marsden Hosp, Sutton, Surrey, England

[42] Inst Canc Res, Div Genet & Epidemiol, Sutton, Surrey, England

[43] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[44] Queensland Inst Med Res, Canc Div, Herston, Qld 4006, Australia

[45] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia

[46] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia

[47] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Dept Gynaecol Oncol, Westmead, NSW 2145, Australia

[48] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia

[49] Univ Copenhagen, Danish Canc Soc, Res Ctr, Copenhagen, Denmark

[50] Univ Copenhagen, Herlev Hosp, Dept Pathol, Mol Unit, Copenhagen, Denmark

来源：

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2014年 / 23卷 / 07期

基金：

英国医学研究理事会;

关键词：

FAMILY MEMBERS; BCL10; RISK; SUSCEPTIBILITY; POLYMORPHISMS; INFLAMMATION; ASSOCIATION; CARD11;

D O I：

10.1158/1055-9965.EPI-13-0962

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-kappa B (NF-kappa B) transcription factor family plays an important role in many immune and inflammatory responses, including the response to cancer. We studied common inherited variation in 210 genes in the NF-kappa B family in 10,084 patients with invasive EOC (5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian Cancer Association Consortium. Associations between genotype and overall survival were assessed using Cox regression for all patients and by major histology, adjusting for known prognostic factors and correcting for multiple testing (threshold for statistical significance, P < 2.5 x 10(-5)). Results were statistically significant when assessed for patients of a single histology. Key associations were with caspase recruitment domain family, member 11 (CARD11) rs41324349 in patients with mucinous EOC [HR, 1.82; 95% confidence interval (CI), 1.41-2.35; P = 4.13 x 10(-6)] and tumor necrosis factor receptor superfamily, member 13B (TNFRSF13B) rs7501462 in patients with endometrioid EOC (HR, 0.68; 95% CI, 0.56-0.82; P = 2.33 x 10(-5)). Other associations of note included TNF receptor-associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77-0.92; P = 6.49 x 10(-5)) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26-0.73; P = 4.56 x 10(-4)). These associations highlight the potential importance of genes associated with host inflammation and immunity in modulating clinical outcomes in distinct EOC histologies. (C)2014 AACR.

引用

页码：1421 / 1427

页数：7

共 50 条

[1] NF-κB Signaling in Ovarian Cancer
Harrington, Brittney S.
Annunziata, Christina M.
CANCERS, 2019, 11 (08)
[2] NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
Devanaboyina, Monika
Kaur, Jasskiran
Whiteley, Emma
Lin, Leslie
Einloth, Katelyn
Morand, Susan
Stanbery, Laura
Hamouda, Danae
Nemunaitis, John
ONCOLOGY REVIEWS, 2022, 16
[3] Polymorphisms in NF-κB Inhibitors and Risk of Epithelial Ovarian Cancer
White, Kristin L.
Vierkant, Robert A.
Phelan, Catherine M.
Fridley, Brooke L.
Anderson, Stephanie
Knutson, Keith L.
Schildkraut, Joellen M.
Cunningham, Julie M.
Kelemen, Linda E.
Pankratz, V. Shane
Rider, David N.
Liebow, Mark
Hartmann, Lynn C.
Sellers, Thomas A.
Goode, Ellen L.
BMC CANCER, 2009, 9
[4] Polymorphisms in NF-κB Inhibitors and Risk of Epithelial Ovarian Cancer
Kristin L White
Robert A Vierkant
Catherine M Phelan
Brooke L Fridley
Stephanie Anderson
Keith L Knutson
Joellen M Schildkraut
Julie M Cunningham
Linda E Kelemen
V Shane Pankratz
David N Rider
Mark Liebow
Lynn C Hartmann
Thomas A Sellers
Ellen L Goode
BMC Cancer, 9
[5] Crosstalk in NF-κB signaling pathways
Oeckinghaus, Andrea
Hayden, Matthew S.
Ghosh, Sankar
NATURE IMMUNOLOGY, 2011, 12 (08) : 695 - 708
[6] Crosstalk in NF-κB signaling pathways
Andrea Oeckinghaus
Matthew S Hayden
Sankar Ghosh
Nature Immunology, 2011, 12 : 695 - 708
[7] Classic and Novel Signaling Pathways Involved in Cancer: Targeting the NF-κB and Syk Signaling Pathways
Tang, Cong
Zhu, Guodong
CURRENT STEM CELL RESEARCH & THERAPY, 2019, 14 (03) : 219 - 225
[8] Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer
White, Kristin L.
Rider, David N.
Kalli, Kimberly R.
Knutson, Keith L.
Jarvik, Gail P.
Goode, Ellen L.
CANCER CAUSES & CONTROL, 2011, 22 (05) : 785 - 801
[9] NF-κB signaling regulates miRNA expression in ovarian cancer.
Kamdar, Rahul D.
Harrington, Brittney S.
Korrapati, Soumya
Wong, Nathan
House, Carrie D.
Annunziata, Christina M.
CANCER RESEARCH, 2022, 82 (12)
[10] Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer
Kristin L. White
David N. Rider
Kimberly R. Kalli
Keith L. Knutson
Gail P. Jarvik
Ellen L. Goode
Cancer Causes & Control, 2011, 22 : 785 - 801

← 1 2 3 4 5 →